Abionic SA
Edit

Abionic SA

http://www.abionic.com/
Last activity: 22.02.2024
Categories: ToolsTechnologySupplyProductPersonalMedTechITHealthTechDiagnosticsBioTech
Abionic SA is positioned at the boundaries of medical technology, biotechnology & nanotechnology and is developing a novel diagnostic tool that will provide patients with personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.
Mentions
67
Location: Switzerland, Vaud, Epalinges
Total raised: $24.94M

Investors 6

Funding Rounds 2

DateSeriesAmountInvestors
29.03.2018Series C$20.91M-
15.10.2014Series B$4.03M-

Mentions in press and media 67

DateTitleDescriptionSource
22.02.2024Startups welcome field experts in C-level roles After more than a decade of building and leading Abionic, the developer of nanofluidic point-of-car...startuptic...
13.06.2023The Swiss Medtech Award 2023 goes to Abionicstartuptic...
10.08.2022Abionic receives IVDR certification for its ultra-rapid Seps...startuptic...
30.04.2021Clinical trial confirms Abionic’s ability to detect Sepsis e...startuptic...
30.04.2021Clinical trial confirms Abionic’s ability to detect Sepsis e...Published recently in the Critical Care Journal, the study was designed to establish performance cha...startuptic...
26.11.2020Abionic launches new tool for faster triage of Covid19 patie...Since the outbreak of the Covid-19 pandemic, countries around the globe have seen increasing occupan...startuptic...
26.11.2020Abionic launches new tool for faster triage of Covid19 patie...startuptic...
20.06.2020Rising out of the crisis: Where to find new markets and cust...The pandemic has upended the business models of most startups and existing companies. As the economy...venturebea...
20.06.2020Rising out of the crisis: Where to find new markets and cust...We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI an...venturebea...
14.01.2020Sepsis in the Focus of Abionic's New U.S. Clinical TrialWe are pleased to share some positive news on our BOV I and BOV II portfolio company Abionic.blueocean-...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In